COVID-19 vaccination and rare side effects, UK Health Security Agency (updated 29th November 2021)
Guidance relating to blood clotting, myocarditis and Guillain-Barr é Syndrome (GBS) after COVID-19 vaccination.
29 November 2021Added myocarditis and pericarditis after COVID-19 vaccination guidance.
18 August 2021First published. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 29, 2021 Category: Consumer Health News Source Type: news
Johnson & Johnson to Evaluate Its COVID-19 Vaccine Against New Omicron COVID-19 Variant
Since the emergence of the COVID-19 pandemic, Johnson & Johnson (the Company) has been closely monitoring newly emerging COVID-19 variants. In collaboration with academic groups in South Africa and around the world, the Company has been evaluating the effectiveness of its COVID-19 vaccine across variants, including now the new and rapidly spreading Omicron variant. The Company is testing blood serum from participants in completed and ongoing booster studies to look for neutralizing activity against the Omicron variant. In addition, the Company is pursuing an Omicron-specific variant vaccine and will progress it as need...
Source: Johnson and Johnson - November 29, 2021 Category: Pharmaceuticals Source Type: news
COVID-19: the green book, chapter 14a, UK Health Security Agency (updated 15th November 2021)
Coronavirus (COVID-19) vaccination information for public health professionals.
15 November 2021Updated to include second doses for 16 to 17 year olds and booster doses for 40 to 49 year olds; further clarification on booster timing flexibility; guidance on deferral after COVID-19 infection in under 18s and other minor edits for clarification.
29 October 2021Updated to improve consistency of wording in the allergy and immunosuppressed sections; updated definitions of clinically vulnerable, advice on further doses for those who have suspected myocarditis or Guillain-Barr é Syndrome after vaccination, clarifying flexi...
Source: Current Awareness Service for Health (CASH) - November 16, 2021 Category: Consumer Health News Source Type: news
Study: Shingrix shingles vaccine riskier for Guillain-Barr é than older shot
Older adults who receive the Shingrix shingles vaccines are more than twice as likely to develop Guillain-Barr é syndrome compared with those given the older Zostavax product, a JAMA Internal Medicine study found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 1, 2021 Category: Consumer Health News Source Type: news
Update to COVID-19 chapter of the green book (chapter 14a), UK Health Security Agency (updated 29th October 2021)
Coronavirus (COVID-19) vaccination information for public health professionals.
29 October 2021Updated to improve consistency of wording in the allergy and immunosuppressed sections; updated definitions of clinically vulnerable, advice on further doses for those who have suspected myocarditis or Guillain-Barr é Syndrome after vaccination, clarifying flexibility around the booster timing and supply, additional evidence on booster dose effectiveness and on vaccination after monoclonal antibody products.
16 September 2021Updated to include new recommendations on boosters and children and young people. Minor updates to ...
Source: Current Awareness Service for Health (CASH) - November 1, 2021 Category: Consumer Health News Source Type: news
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection, Nature Medicine
Analysis of self-controlled case series notes although there was increased risk of neurological complications in those who received COVID-19 vaccines, risk is greater following positive SARS-CoV-2 test (38 vs. 145 excess cases of Guillain –Barr é syndrome/10 million, respectively). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 27, 2021 Category: Consumer Health News Source Type: news
Covid: Vaccine study links virus to rare neurological illness
Guillain-Barre Syndrome is more likely to occur in people who catch Covid, study finds. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - October 25, 2021 Category: Consumer Health News Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
U.S. CDC Advisory Committee Unanimously Recommends Johnson & Johnson COVID-19 Vaccine as a Booster for All Eligible Individuals Who Receive Authorized COVID-19 Vaccines
NEW BRUNSWICK, N.J., October 21, 2021 – Johnson & Johnson (the Company) today announced that the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), has recommended its COVID-19 vaccine as a booster for all eligible individuals who receive an authorized COVID-19 vaccine. “Today’s recommendation supports the use of the Johnson & Johnson COVID-19 vaccine as a booster for eligible individuals in the U.S. regardless of which vaccine they initially receive,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Jo...
Source: Johnson and Johnson - October 21, 2021 Category: Pharmaceuticals Source Type: news
CDC Authorizes Boosters of Moderna and Johnson & Johnson COVID-19 Vaccines
Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), authorized booster doses of COVID-19 vaccines for certain groups. Walensky followed the advice of a CDC expert panel, which recommended the boosters in in two unanimous votes earlier in the day.
The 15-member Advisory Committee on Immunization Practices (ACIP) advised that anyone who was initially vaccinated with the Moderna shot get a booster at least six months later, and that J&J-Janssen recipients receive a booster at least two months after their initial vaccination. The endorsement follows a similar decision from the Food and ...
Source: TIME: Health - October 21, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
CDC Authorizes Boosters of Moderna and Johnson & Johnson COVID-19 Vaccines
Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), authorized booster doses of COVID-19 vaccines for certain groups. Walensky followed the advice of a CDC expert panel, which recommended the boosters in in two unanimous votes earlier in the day.
The 15-member Advisory Committee on Immunization Practices (ACIP) advised that anyone who was initially vaccinated with the Moderna shot get a booster at least six months later, and that J&J-Janssen recipients receive a booster at least two months after their initial vaccination. The endorsement follows a similar decision from the Food and ...
Source: TIME: Health - October 21, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
NEW BRUNSWICK, N.J., October 20, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine. The Johnson & Johnson booster shot will be the same formulation and dosage as the primary shot. The EUA follows a unanimous recommendat...
Source: Johnson and Johnson - October 20, 2021 Category: Pharmaceuticals Tags: Latest News Source Type: news
Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
NEW BRUNSWICK, N.J., October 15, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 19-0 to recommend Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine. The vote was based on findings from two Company clinical trials, including the Phase 3 ENSEMBLE 2 study, which evaluated a booster dose of the Johnson & Johnso...
Source: Johnson and Johnson - October 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Pandemic Data Challenges Infection Link to Guillain-Barr é Pandemic Data Challenges Infection Link to Guillain-Barr é
Armed with data from the COVID-19 pandemic, researchers are suggesting that most cases of Guillain-Barr é syndrome are not connected to infectious disease after all.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 13, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Johnson & Johnson Announces Submission of Emergency Use Authorization Amendment to the U.S. FDA to Support Booster of its Single-Shot COVID-19 Vaccine
NEW BRUNSWICK, N.J., October 05, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) announced it has submitted data to the U.S. Food and Drug Administration (FDA) to support use of a booster shot of the Johnson & Johnson COVID-19 vaccine in individuals 18 years of age and older.The submission includes recent results from the Phase 3 ENSEMBLE 2 study that found a booster of the Johnson & Johnson COVID-19 vaccine given 56 days after the primary dose provided 94 percent protection against symptomatic (moderate to severe/critical) COVID-19 in the U.S. (CI, 58%-100%) and 100 percent protection (CI, 33%-100%) again...
Source: Johnson and Johnson - October 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
